share_log

8-K: Current report

8-K: Current report

8-K:重大事件
美股SEC公告 ·  04/16 16:42

Moomoo AI 已提取核心訊息

Adial Pharmaceuticals, Inc., a Delaware-incorporated company listed on the Nasdaq Capital Market under the trading symbol ADIL, has filed a Form 8-K with the United States Securities and Exchange Commission on April 10, 2024. The report announces the termination of the consulting agreement with Dr. Bankole A. Johnson, who has served as the company's Chief Medical Officer. The agreement, which began on March 24, 2019, and was amended on March 22, 2022, and September 8, 2022, will be effectively terminated on May 17, 2024. Following this date, Dr. Johnson will no longer hold the position of Chief Medical Officer at Adial Pharmaceuticals. The company has fulfilled the SEC's requirements by having the report signed by President and Chief Executive Officer Cary J. Claiborne.
Adial Pharmaceuticals, Inc., a Delaware-incorporated company listed on the Nasdaq Capital Market under the trading symbol ADIL, has filed a Form 8-K with the United States Securities and Exchange Commission on April 10, 2024. The report announces the termination of the consulting agreement with Dr. Bankole A. Johnson, who has served as the company's Chief Medical Officer. The agreement, which began on March 24, 2019, and was amended on March 22, 2022, and September 8, 2022, will be effectively terminated on May 17, 2024. Following this date, Dr. Johnson will no longer hold the position of Chief Medical Officer at Adial Pharmaceuticals. The company has fulfilled the SEC's requirements by having the report signed by President and Chief Executive Officer Cary J. Claiborne.
Adial Pharmicals, Inc. 是一家在納斯達克資本市場上市的特拉華州註冊公司,交易代碼爲ADIL,該公司已於2024年4月10日向美國證券交易委員會提交了8-K表格。該報告宣佈終止與曾擔任公司首席醫療官的班科爾·約翰遜博士的諮詢協議。該協議於2019年3月24日開始,於2022年3月22日和2022年9月8日進行了修訂,將於2024年5月17日有效終止。此後,約翰遜博士將不再在Adial Pharmicals擔任首席醫學官一職。該公司由總裁兼首席執行官卡里·克萊伯恩簽署了報告,從而滿足了美國證券交易委員會的要求。
Adial Pharmicals, Inc. 是一家在納斯達克資本市場上市的特拉華州註冊公司,交易代碼爲ADIL,該公司已於2024年4月10日向美國證券交易委員會提交了8-K表格。該報告宣佈終止與曾擔任公司首席醫療官的班科爾·約翰遜博士的諮詢協議。該協議於2019年3月24日開始,於2022年3月22日和2022年9月8日進行了修訂,將於2024年5月17日有效終止。此後,約翰遜博士將不再在Adial Pharmicals擔任首席醫學官一職。該公司由總裁兼首席執行官卡里·克萊伯恩簽署了報告,從而滿足了美國證券交易委員會的要求。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息